Concepedia

Garry Beran

GB

Statistics

Publications

8

Citations

1K

H-Index

8

Active since

2009

Affiliations

AstraZeneca (United Kingdom)(Current)

AstraZeneca (United States)

Garry Beran is an author at AstraZeneca (United Kingdom) specializing in medicine, molecular oncology, and oncology.

Publications per year

2009–2016

8

Publications

8

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Catherine A. Eberlein, Daniel Stetson, Aleksandra Markovets et al. · Cancer Research · 2015 · 300 citations · Full text

Medicine, Oncology, Pharmacology +17

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas et al. · Cancer Research · 2010 · 264 citations · Full text

Medicine, Oncology, Pharmacology +17

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

Andreas Schlicker, Garry Beran, Christine M. Chresta et al. · BMC Medical Genomics · 2012 · 257 citations · Full text

Medicine, Cancer Biology, Oncology +17

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

Alwin G. Schuller, Evan Barry, Rhys D.O. Jones et al. · Clinical Cancer Research · 2015 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers

James Bradford, Mark Wappett, Garry Beran et al. · Oncotarget · 2016 · 43 citations · Full text

Medicine, Cancer Biology, Molecular Biology +17

1–5 of 8